

# Personalisierte Onkologie im Fokus

## Geschlechterspezifische Unterschiede bei Immun- und Zelltherapien in der Onkologie

P. Warncke, S. Fricke, U. Seeland, U. Köhl, A. Morgner, M. v. Bonin, V. Vučinić, K. Jöhrens, M. Bornhäuser, K. Metzeler, M. Hänel

### Literatur

- [1] Bernardez B, Higuera O, Martinez-Callejo V, Cardeña-Gutiérrez A, Marcos Rodríguez JA, Santaballa Bertrán A et al. Sex and gender differences in cancer pathogenesis and pharmacology. *Clin Transl Oncol*. 2025. DOI: 10.1007/s12094-025-03894-1
- [2] Wagner AD. Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy. *ESMO Open*. 2020;5(5):e000770. DOI: 10.1136/esmoopen-2020-000770
- [3] Grassadonia A, Carletti E, De Luca A, Vici P, Di Lisa FS, Filomeno L et al. Prognostic value of gender and primary tumor location in metastatic colon cancer. *J Cancer*. 2023;14(15):2751–8. DOI: 10.7150/jca.85748
- [4] Ma J, Yao Y, Tian Y, Chen K, Liu B. Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. *Biol Sex Differ*. 2022;13(1):58. DOI: 10.1186/s13293-022-00469-5
- [5] Delahousse J, Wagner AD, Borchmann S, Adjei AA, Haanen J, Burgers F et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. *ESMO Open*. 2024;9(12):104002. DOI: 10.1016/j.esmoop.2024.104002
- [6] Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M et al. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. *Br J Haematol*. 2017 Nov;179(3):410–420. DOI: 10.1111/bjh.14860.
- [7] Sharma S, Gibbons A, Saphire EO. Sex differences in tissue-specific immunity and immunology. *Science*. 2025;389(6760):599–603. DOI: 10.1126/science.adx4381
- [8] Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626–38. DOI: 10.1038/nri.2016.90
- [9] Fairweather D, Frisancho-Kiss S, Rose NR. Sex Differences in Autoimmune Disease from a Pathological Perspective. *Am J Pathol*. 2008;173(3):600–9. DOI: 10.2353/ajpath.2008.071008
- [10] Desai MK, Brinton RD. Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. *Front Endocrinol (Lausanne)*. 2019;10:265. DOI: 10.3389/fendo.2019.00265
- [11] Wang S, Cowley LA, Liu XS. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. *Molecules*. 2019;24(18):3214. DOI: 10.3390/molecules24183214
- [12] Heinze A, Elze MC, Kloess S, Ciocarlie O, Königs C, Betz S et al. Age-matched dendritic cell subpopulations reference values in childhood. *Scand J Immunol*. 2013 Mar;77(3):213–20. DOI: 10.1111/sji.12024. PMID:

- [13] Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. *Lancet Oncol.* 2018;19(6):737–46. DOI: 10.1016/S1470-2045(18)30261-4
- [14] Liang J, Hong J, Tang X, Qiu X, Zhu K, Zhou L, et al. Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. *Ann Med.* 2022;54(1):2606–16. DOI: 10.1080/07853890.2022.2124449
- [15] Santaballa Bertrán A, Marcos Rodríguez JA, Cardeña-Gutiérrez A, Martínez-Callejo V, Higuera O, Bernardez B et al. Sex-related differences in the efficacy and toxicity of cancer treatments. *Clin Transl Oncol.* 2025; 27:3636–3646. DOI: 10.1007/s12094-025-03893-2
- [16] Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. *J Clin Oncol.* 2022;40(13):1474–86. DOI: 10.1200/JCO.21.02377
- [17] Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H et al. Sex-associated molecular differences for cancer immunotherapy. *Nat Commun.* 2020;11(1):1779. DOI: 10.1038/s41467-020-15679-x
- [18] Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q et al. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. *Br J Haematol.* 2023;201(4):e37–41. DOI: 10.1111/bjh.18753
- [19] Posch D, Rabitsch W, Wohlfarth P, Leiner M, Porpaczy E, Drach J et al. Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. *Oncology.* 2017;93(5):295–301. DOI: 10.1159/000478265
- [20] Heini AD, Kammermann K, Bacher U, Jeker B, Hayoz M, Aebi Y et al. Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma. *Cancers (Basel).* 2024;16(19):3364. DOI: 10.3390/cancers16193364
- [21] Kim HT, Zhang MJ, Woolfrey AE, Martin AS, Chen J, Saber W et al. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. *Haematologica.* 2016;101(10):1260–6. DOI: 10.3324/haematol.2016.147645
- [22] Nakasone H, Remberger M, Tian L, Brodin P, Sahaf B, Wu F, et al. Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. *Haematologica.* 2015;100(11):1477–85. DOI: 10.3324/haematol.2015.125294
- [23] Ali N, Ullah H, Shaikh MU, Adil SN. Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure. *Int J Hematol Oncol.* 2019;8(4):IJH21. DOI: 10.2217/ijh-2019-0006
- [24] Larue M, Labopin M, Schroeder T, Huang X jun, Blau IW, Schetelig J et al. Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia. *HemaSphere.* 2024;8(10):e70026. DOI: 10.1002/hem3.70026
- [25] Carreras E, Dufour C, Mohty M, Kröger N (Editors). *The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies.* 7th Edition, Springer; 2019. DOI: 10.1007/978-3-030-02278-5
- [26] Ussmann, J., Bischof, L., Backhaus, D. et al. Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. *Blood Cancer J.* 15, 107 (2025). DOI: 10.1038/s41408-025-01316-7

- [27] Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2019;380(1):45–56. DOI: 10.1056/NEJMoa1804980
- [28] Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, u. a. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med.* 2021;384(8):705–16. DOI: 10.1056/NEJMoa2024850
- [29] Tan JY, Yeo YH, Kin HWK, Ang QX, Chisti MM, Ezekwudo D et al. Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy. *Cancer Med.* 2025;14(6):e70831. DOI: 10.1002/cam4.70831
- [30] Buecklein VL, Rejeski K, Perez A, Iacoboni G, Jurinovic V, Kharboutli S et al. Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients. *Blood.* 2023;142(Supplement 1):3787. DOI: 10.1182/blood-2023-186510
- [31] Fabbri N, Peña M, Barba P, Iacoboni G, Kwon M, Bailen R et al. Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study. *Blood.* 2023;142(Supplement 1):6895. DOI: 10.1182/blood-2023-185721
- [32] Gupta N, Patel MS, Jalota A, Mian A, Bazeley P, Hunter SA et al. Sex differences in the pre-treatment cytokine signatures associated with response and survival in B cell lymphoma patients treated with anti-CD19 CAR T-cell therapy. *J Immunol.* 1 2022;208(Supplement\_1):66.10. 10.4049/jimmunol.208.Supp.66.10
- [33] Singh R, Gopinath C, Mejia I, Bechara SB, Carfagnini C, Kandula M, u. a. Assessing Gender and Racial Inclusion in CAR-T Cell Therapy Clinical Studies: A Scoping Review. *Blood.* 2024;144:7815. DOI: /10.1182/blood-2024-210720
- [34] Jenei K, Meyers DE, Prasad V. The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. *JAMA Oncol.* 2021;7(10):1569–70. DOI: 10.1001/jamaoncol.2021.3686
- [35] Alpert AB, Nagle SA, Greer MJ, Meacham PJ, Macdowell P, Gerbino N et al. A Novel Method for Identifying Transgender and Gender Diverse Patients with Lymphoma: A Single Center Experience. *Blood.* 2019;134:5825. DOI: 10.1182/blood-2019-126884
- [36] Cathcart-Rake EJ, Chan A, Menendez A, Markstrom D, Schnitzlein C, Chong YW et al. Cancer care for transgender and gender-diverse people: Practical, literature-driven recommendations from the Multinational Association of Supportive Care in Cancer. *CA Cancer J Clin.* 2025;75(1):68–81. DOI: 10.3322/caac.21872
- [37] Keiner D. Gendermedizin: „Wir stehen erst am Anfang“. *Dtsch Ärztebl.* 2017;114(5):[4]. DOI: 10.3238/PersOnko/2017.02.03.01
- [38] Özdemir BC, Oertelt-Prigione S, Adjei AA, Borchmann S, Haanen JB, Letsch A, u. a. Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. *Ann Oncol.* 2022;33(2):126–8. DOI: 10.1016/j.annonc.2021.11.011